Please wait a minute...
Clinical and Experimental Obstetrics & Gynecology  2021, Vol. 48 Issue (5): 1032-1043    DOI: 10.31083/j.ceog4805166
Special Issue: Complementary and Integrative Therapies for Women's Health
Systematic Review Previous articles | Next articles
The effects of Chinese herbal medicine on the pregnancy outcomes of infertile women with polycystic ovary syndrome undergoing in vitro fertilization-embryo transfer: a systematic review and meta-analysis
Chang Liu1, Minchen Dai2, Lei Zhao1, *(), Fangfang Wang3, *()
1The Second Department of Clinical Medicine, Zhejiang Chinese Medical University, 310053 Hangzhou, Zhejiang, China
2Department of Traditional Chinese Medicine, Women's Hospital, School of Medicine, Zhejiang University, 310006 Hangzhou, Zhejiang, China
3Department of Obstetrics and Gynecology, Women's Hospital, School of Medicine, Zhejiang University, 310006 Hangzhou, Zhejiang, China
Download:  PDF(2419KB)  ( 77 ) Full text   ( 24 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Background: At present, Chinese herbal medicine (CHM) has already been widely used as an important adjuvant treatment for polycystic ovary syndrome (PCOS) patients undergoing in vitro fertilization-embryo transfer (IVF-ET). This systematic review and meta-analysis were designed to evaluate the effects of CHM on the pregnancy outcomes of infertile women with PCOS undergoing IVF-ET. Methods: We searched seven electronic databases systematically for published articles to January 2021. All randomized controlled trials (RCTs) comparing CHM with blank or placebo for infertile PCOS patients undergoing IVF-ET were included. The measures of treatment effect were the pooled odds ratios (OR) of the clinical pregnancy rate, the abortion rate and the ovarian hyperstimulation syndrome (OHSS) incidence. Results: This meta-analysis included 10 studies involving 663 patients comparing CHM with blank or placebo for infertile PCOS patients undergoing IVF-ET. The pooled data showed that CHM could improve the clinical pregnancy rate (OR = 2.41, 95% CI: 1.73–3.35, p < 0.01) and reduce the OHSS incidence (OR = 0.31, 95% CI: 0.18–0.55, p < 0.01) of infertile PCOS patients with IVF-ET treatment. No significant difference in the abortion rate was found between the CHM and control groups (OR = 0.64, 95% CI: 0.23–1.81, p = 0.40). Discussion: CHM can be used as an auxiliary treatment for infertile PCOS patients undergoing IVF-ET.
Key words:  In vitro fertilization-embryo transfer      Chinese herbal medicine      Polycystic ovary syndrome     
Submitted:  22 June 2021      Revised:  12 August 2021      Accepted:  26 August 2021      Published:  15 October 2021     
Fund: 
81873837/National Natural Science Foundation of China to FW
2018YFC1004900/National Key R&D Program of China to FW
*Corresponding Author(s):  drwangfangfang@zju.edu.cn (Fangfang Wang); zhaolei2351@126.com (Lei Zhao)   

Cite this article: 

Chang Liu, Minchen Dai, Lei Zhao, Fangfang Wang. The effects of Chinese herbal medicine on the pregnancy outcomes of infertile women with polycystic ovary syndrome undergoing in vitro fertilization-embryo transfer: a systematic review and meta-analysis. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(5): 1032-1043.

URL: 

https://ceog.imrpress.com/EN/10.31083/j.ceog4805166     OR     https://ceog.imrpress.com/EN/Y2021/V48/I5/1032

[1] Zhenzhen Lu, Ying Gao. Searching for biomarkers in the progression from polycystic ovary syndrome to endometrial carcinoma[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(5): 1117-1125.
[2] Gonca Özten Dere, Esra Uyanik, Fatih Aktoz, Pınar Çalış, Sezcan Mümüşoğlu, Hakan Yarali, Gürkan Bozdağ. The effect of laparoscopic ovarian drilling on timing of menopause in patients with polycystic ovary syndrome: 29 years of follow-up data[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(3): 590-593.
[3] Hye Won Lee, Lin Ang, Myeong Soo Lee, Kyoung Sun Park, Jin-Moo Lee, Chang-Hoon Lee, Dong Chul Kim, Jeong-Eun Yoo, Seung-Jeong Yang, Tae-Young Choi. Prescription patterns of herbal medicine for polycystic ovarian syndrome in major Korean medicine hospitals: a multicenter retrospective study[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(3): 649-653.
[4] J. Dun, X. Wang, J. Yang, J. Xu. Clinical practice guidelines on polycystic ovary syndrome: a systematic review and comparative meta-analysis[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(4): 465-471.
[5] Xiao-Tao Huang, Shao-Rong Liang, Lu Wang. Acupuncture combined with Chinese and western medicine in the treatment of polycystic ovary syndrome[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(3): 396-400.
[6] A. M. Maysara, A. T. Nassar, H. K. Jubran. The effect of correction of serum level of vitamin D on hyperandrogenism in women with polycystic ovary syndrome and hypovitaminosis D[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(2): 272-276.
[7] H.M.G. Youssef, E.S. Marei, L.A. Rashed. Long non-coding RNA steroid receptor activator in polycystic ovary syndrome: possible association with metabolic syndrome[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(5): 757-762.
[8] M.H. Vieira de Melo, M.T. Albuquerque Barbosa Cabral Micussi, R. Dias de Medeiros, R. Ney Cobucci, T.M. de Oliveira Maranhão, A.K. Gonçalves. Pelvic floor muscle thickness in women with polycystic ovary syndrome[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(6): 813-816.
[9] Hui-lan Wang, Xia Xu, Zhi-qun Zheng. The expression of Nuclear Factor-κB in a rat model of polycystic ovary syndrome[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(2): 276-279.
[10] P. Marques, F. Ferreira, A. P. Soares, J. Nunes, S. Sousa, A. Aguiar, C. Calhaz-Jorge. Clinico-biochemical characteristics of 229 Portuguese infertile women with polycystic ovary syndrome: clinical relevance and relationship with fertility treatment results[J]. Clinical and Experimental Obstetrics & Gynecology, 2016, 43(6): 812-817.
[11] L. H. Sordia-Hernández, P. Ancer Rodríguez, D. Saldivar Rodriguez, S. Trejo Guzmán, E. S. Servín Zenteno, G. Guerrero González, R. Ibarra Patiño. Effect of a low glycemic diet in patients with polycystic ovary syndrome and anovulation - a randomized controlled trial[J]. Clinical and Experimental Obstetrics & Gynecology, 2016, 43(4): 555-559.
[12] S. Hacivelioglu, A. Uysal, A.N. Cakir Gungor, M. Gencer, D.U. Cakir, E. Cosar. The effect of maternal polycystic ovary morphology on first-trimester maternal serum biochemical markers of aneuploidy and fetal nuchal translucency thickness[J]. Clinical and Experimental Obstetrics & Gynecology, 2015, 42(1): 32-35.
[13] W. Li, Y. Chen, L. Xu. Association of sympathetic nervous system activity with polycystic ovarian syndrome[J]. Clinical and Experimental Obstetrics & Gynecology, 2014, 41(5): 499-506.
[14] L. Hu, H. Shen, Q.F. Wu, L. Tian, M.H. Hu. Treatment of polycystic ovarian syndrome with insulin resistance by insulin-sensitizer[J]. Clinical and Experimental Obstetrics & Gynecology, 2014, 41(3): 288-292.
[15] Yueqiao Zhen, Peng Yang, Ruihong Dong, Yumin Wu, Yanhong Sang, Xiaoxiao Du, Yan Wang, Qiuyan Song, Ling Yu, Xiaojuan Rao. Effect of HbA1C detection on the diagnostic screening for glucose metabolic disorders in polycystic ovary syndrome[J]. Clinical and Experimental Obstetrics & Gynecology, 2014, 41(1): 58-61.
No Suggested Reading articles found!